Skip to main content

Table 2 Disease Characteristics for Respondents With MPNs Employed at Diagnosis

From: Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey

 

MF (n = 174)

PV (n = 248)

ET (n = 170)

All MPNs (n = 592)

Duration of disease, mean (SD), y

4.6 (4.7)

6.9 (7.2)

6.3 (6.4)

6.1 (6.4)

Risk score at any time during treatment

 High

25 (14.4)

35 (14.1)

41 (24.1)

101 (17.1)

 Intermediate

61 (35.1)

29 (11.7)

21 (12.4)

111 (18.8)

 Low

17 (9.8)

22 (8.9)

34 (20.0)

73 (12.3)

 Not available or did not recall

71 (40.8)

162 (65.3)

74 (43.5)

307 (51.9)

Comorbid conditions ever diagnosed*

 Diabetes

28 (16.1)

21 (8.5)

9 (5.3)

58 (9.8)

 Solid tumor

13 (7.5)

12 (4.8)

9 (5.3)

34 (5.7)

 Emphysema or COPD

9 (5.2)

13 (5.2)

5 (2.9)

27 (4.6)

 Connective tissue disorders

8 (4.6)

8 (3.2)

10 (5.9)

26 (4.4)

 Moderate to severe kidney disease

13 (7.5)

8 (3.2)

3 (1.8)

24 (4.1)

 Liver disease

7 (4.0)

9 (3.6)

4 (2.4)

20 (3.4)

History of thrombotic events, n (%)

40 (23.0)

51 (20.6)

37 (21.8)

128 (21.6)

  1. COPD, chronic obstructive pulmonary disease; ET, essential thrombocythemia; MF, myelofibrosis; MPN, myeloproliferative neoplasm; PV, polycythemia vera
  2. *Occurring in > 3% of all respondents employed at diagnosis
  3. Each respondent could have > 1 thrombotic event